

«HELLENIC REPUBLIC  
MINISTRY OF EMPLOYMENT & SOCIAL INSURANCE  
GENERAL SECRETARIAT OF SOCIAL INSURANCE  
DIRECTORATE OF PATIENTS INSURANCE & MATERNITY  
Prot. No. Φ80000/οικ.11385/1394

Athens, April 30, 2010

SUBJECT: «APPROVAL OF LIST OF MEDICINAL PRODUCTS ADMINISTERED ACCORDING TO ARTICLE 12,  
PAR. 2 OF L. 3816/2010 (OJ A', P. 6)

THE MINISTERS OF  
ECONOMY, COMPETITIVENESS & SHIPPING  
EMPLOYMENT & SOCIAL INSURANCE  
AND  
HEALTH & SOCIAL WELFARE

Taking into consideration:

1. The provisions of article 12 par. 2 passage. "c" of L. 3816/2010 (OJ A,6),
2. No. 622/3-3-2010 document of the National Organization for Medicines,
3. The joint ministerial decision 3α/Γ.Π.151509/19-12-08 (OJ B' 2717),
4. The fact that the present decision does not create any burden neither to the budget of the State nor to the budget of the social insurance funds,
5. The market decrees No A3/766/31-3-2010 and No A3/1162/29-4-2010

we decide:

The out-patients who are insured at the civil servants insurance fund and the patients insured at social insurance funds which belong to the General Secretariat of Insurance Funds or those entitled healthcare according to special provisions for the treatment of serious diseases may obtain without co-payment from pharmacies of public hospitals and private pharmacies the following medicinal products:

<b>N</b>	<b>NAME OF THE MEDICINAL PRODUCT</b>	<b>ACTIVE INGREDIENT</b>
1.	ALIMTA	PEMETREXED DISODIUM
2.	ANZEMET	DOLASETRON MESILATE
3.	ARANESP	DARBEPOETIN ALFA
4.	AVASTIN	BEVACIZUMAB
5.	AVONEX	INTERFERON BETA 1A

6.	BEROMUN	TASONERMIN
7.	BETAFERON	INTERFERON BETA 1B RECOMBINANT
8.	CAELYX	DOXORUBICIN
9.	CAMPTO	IRINOTECAN
10.	CERTICAN	EVEROLIMUS
11.	COPAXONE	GLATIRAMER ACETATE
12.	CYMEVENE	GANCICLOVIR SODIUM
13.	ENBREL	ETANERCEPT
14.	EPREX	EPOETINUM ALFA
15.	ETHYOL	AMIFOSTINE TRIHYDRATE
16.	FLEBOGAMMA	IMMUNOGLOBULIN HUMAN NORMAL
17.	GAMMAGARD SD	IMMUNOGLOBULIN HUMAN NORMAL
18.	GRANOCYTE	LENOGRASTIM
19.	GRANULOKINE	FILGRASTIM
20.	HEPSERA	ADEFOVIR DIPIVOXIL
21.	HERCEPTIN	TRASTUZUMAB
22.	HUMIRA	ADALIMUMAB
23.	HYCAMTIN	TOPOTECAN HYDROCHLORIDE
24.	INTRAGLOBIN F	IMMUNOGLOBULIN HUMAN NORMAL
25.	INTRATECT	IMMUNOGLOBULIN HUMAN NORMAL
26.	INTRONA	INTERFERON ALFA 2B
27.	KEPIVANCE	PALIFERMIN
28.	KINERET	ANANKIRA
29.	KIOVIG	IMMUNOGLOBULIN HUMAN NORMAL
30.	LEUSTATIN	CLADRIBINE
31.	LUCENTIS	RANIBIZUMAB
32.	MABCAMPATH	ALEMTUZUMAB
33.	MABTHERA	RITUXIMAB
34.	MACUGEN	PEGAPTANIB SODIUM
35.	MIRCERA	METHOXY POLYETHYLENE GLYCOL – EPOETIN BETA
36.	MYFORTIC	MYCOPHENOLIC ACID
37.	MYOCET	DOXORUBICIN
38.	NAVELBINE	VINORELBINE DITARTATE
39.	NEORECORMON	EPOETIN BETA
40.	NEULASTA	PEGFILGRASTIM
41.	NEXAVAR	SOPAFENIB
42.	OCTAGAM	IMMUNOGLOBULIN HUMAN NORMAL
43.	ORENCIA	ABATACEPT

44.	OVAPAC	PACLITAXEL
45.	PACLITAXEL / GENERICS	PACLITAXEL
46.	PACLITAXEL / HOSPIRA	PACLITAXEL
47.	PACLITOL	PACLITAXEL
48.	PACLIXEL	PACLITAXEL
49.	PATAXEL	PACLITAXEL
50.	PAXENE	PACLITAXEL
51.	PAXENE PACLITAXEL	PACLITAXEL
52.	PEGASYS	PEGINTERFERONE ALFA 2 A
53.	PEGINTRON	PEGINTERFERON ALFA – 2B
54.	PENTAGLOBIN	IMMUNOGLOBULIN HUMAN NORMAL
55.	PROGRAF	TACROLIMUS
56.	RAPAMUNE	SIROLIMUS
57.	REBIF	INTERFERON BETA 1A
58.	REMICADE	INFLIXIMAB
59.	REMODULIN	TREPROSTINIL SODIUM
60.	RETACRIT	EPOETIN ZETA
61.	REVATIO	SILDENAFIL
62.	REVLIMID	LENALIDOMIDE
63.	RILUTEK	RILUZOLE
64.	ROFERON – A	INTERFERON ALFA 2A RECOMBINANT
65.	SANDOGLOBULIN	IMMUNOGLOBULIN HUMAN NORMAL
66.	SANDOSTATIN LAR	OCTREOTIDE ACETATE
67.	SIMULECT	BASILIXIMAB
68.	SPRYCEL	DASATINIB
69.	SUBCUVIA	IMMUNOGLOBULIN HUMAN NORMAL
70.	SUTENT	SUNITINIB
71.	TARCEVA	ERLOTINIB
72.	TASIGNA	NILOTINIB
73.	TAXOL	PACLITAXEL
74.	TAXOPROL	PACLITAXEL
75.	TAXOTERE	DOCETAXEL
76.	TEMODAL	TEMOZOLOMID
77.	THELIN	SITAXENTAN SODIUM
78.	TORISEL	TEMSIROLIMUS
79.	TRACLEER	BOSENTAN
80.	TRISENOX	ARSENIC TRIOXIDE
81.	TYSABRI	NATALIZUMAB

82.	TYVERB	LAPATINIBE
83.	VECTIBIX	PANITUMUMAB
84.	VELCADE	BORTEZOMIB
85.	VENTAVIS	ILOPROST
86.	VIVAGLOBIN	IMMUNOGLOBULIN HUMAN NORMAL
87.	VOLIBRIS	AMBRISENTAN
88.	YONDELIS	TRABECTEDIN
89.	ZAVESCA	MIGLUSTAT

All the above mentioned medicinal products are distributed without patient's co-payment and only for the approved by the National Organization for Medicines indications, in every form and strength of their active ingredient and in any package available at the pharmacies of public hospitals.

The hospital submits to the competent insurance fund and to the civil servants insurance fund the executed prescriptions in an all-inclusive list which is divided according to the insurance fund and includes the total cost.

The prescription is accompanied by the opinion of the treating physician who made the diagnosis in the public hospital or the private clinic and, required a special document of its administration, by the marketing authorization.

The civil servants insurance fund and the social insurance funds are charged at the official wholesale price increased by 3% plus the legal surcharges for the purchase of the above mentioned medicinal products from the hospitals. The social insurance fund is obliged to redeem the cost immediately and, in case of difference after the control of the prescriptions, a refinement follows at the next account.

In case the pharmacy of the public hospital cannot administer the medicinal product, the indication "**not available**" is written on the prescription accompanied by the signature of the hospital pharmacist to whom the patient was addressed and the seal of the public hospital. Following that, the prescription is executed at a private pharmacy and must be **accompanied by the above mentioned supporting documents with no co-payment by the beneficiary.**

Private pharmacies which execute prescriptions with the indication "not available", charge the civil servants insurance fund and the social insurance funds the medicinal products of the above list at the **hospital price increased by the legal profit margin plus VAT.** Private pharmacies submit to the competent insurance funds and to the civil servants insurance fund the executed prescriptions, on which the authenticity tape of the medicinal products is adhered, a list of the patients/beneficiaries, grouped according to the insurance fund, to which they belong and the total cost.

The beneficiaries of IKA-ETAM obtain the medicinal products referred to in the list from the pharmacy of the Institution. In case the supply of these medicinal products is not possible at the pharmacy of the Institution they obtain from the public hospitals in the place of their residence according to the procedure described above.

Certified copies of the original prescriptions are kept by the pharmacies of public hospitals for two years for administration purposes.

Public hospitals must plan and have sufficient available supplies to provide to patients, especially the medicines required per medical specialization of each hospital department.

The present decision is valid from the day following its publication at the Official Journal.

The present decision must be published at the Official Journal.

*Athens, April 30, 2010.*

ECONOMY,  
COMPETITIVENESS & SHIPPING

*LOUKIA KATSELI*

THE MINISTERS OF

EMPLOYMENT  
& SOCIAL INSURANCE

*ANDREAS LOVERDOS*

HEALTH &  
PUBLIC SOLIDARITY

*MARIA-ELIZA  
XENOGIANNAKOPOULOU*".